Tempest Announces Inducement Grant Under Nasdaq Listing Rule
Tempest Therapeutics, Inc. (Nasdaq: TPST), a biotechnology company in the clinical stage that is focused on developing innovative targeted and immune-mediated therapies for cancer, has revealed that the Compensation Committee of its Board of Directors has granted an employee nonqualified stock options, allowing the purchase of a total of 60,000 shares of its common stock under the Company’s 2023 Inducement Plan.
Details of the Stock Option Grant
The stock options will vest over a four-year timeframe. Specifically, 25% of these options will become available on the first anniversary of the employee’s start date, while the remaining shares will vest at a rate of 1/48th each month thereafter, provided the employee remains with the company at each vesting date. This structured vesting approach not only motivates the employee but also aligns their interests with the company's long-term objectives.
About Tempest Therapeutics
Tempest Therapeutics is dedicated to advancing a diverse range of small molecule product candidates that utilize tumor-targeted and/or immune-mediated mechanisms to potentially treat various tumors. The company’s innovative research spans from early-stage investigations to more advanced clinical trials, including a randomized global study aimed at first-line cancer patients. This reflects Tempest's commitment to redefining cancer treatment through carefully developed therapies.
Company’s Vision and Goals
At the core of Tempest Therapeutics is a visionary approach to oncology that merges cutting-edge research with practical application. The company is committed to developing transformative therapies that can significantly enhance patient outcomes and prolong survival in difficult cancer cases. By concentrating on both the breadth of development and the depth of therapeutic options, Tempest is uniquely equipped to tackle a wide range of oncological challenges.
Strategic Partnerships and Collaborations
Tempest Therapeutics understands the critical role of collaboration and strategic partnerships in bolstering its research and development initiatives. By partnering with leading research institutions and other biopharmaceutical companies, they enhance their capacity for innovation and expedite the progress of their therapeutic candidates.
Future Prospects
As Tempest looks to the future, it is well-positioned for growth. With ongoing clinical trials and the accumulation of additional data, the company remains committed to advancing its pipeline. The strategic choices made today, supported by skilled leadership and scientific expertise, are laying the foundation for significant advancements in cancer treatment.
Investor & Media Contacts
For any inquiries or further information, please reach out to:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Frequently Asked Questions
What is the purpose of the stock option grant?
The stock option grant is designed to motivate employees by aligning their interests with the long-term goals of the company.
How many shares were included in the stock options grant?
The stock options granted included a total of 60,000 shares of common stock.
What does Tempest Therapeutics focus on?
Tempest Therapeutics specializes in developing targeted and immune-mediated therapies for cancer treatment.
How is the vesting schedule structured for stock options?
The vesting schedule is structured so that 25% of the options vest on the first anniversary of the employee's start date, with the remaining shares vesting monthly thereafter.
Who can be contacted for more information about Tempest Therapeutics?
For investor and media inquiries, you can contact Sylvia Wheeler or Aljanae Reynolds at Wheelhouse Life Science Advisors.
